【汇宇制药:HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验获得批准】汇宇制药公告,全资子公司汇宇海玥收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验获得批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.